The FDA approved Baxter International's cardiovascular medication Bivalirudin Monday.
Here are three things to know.
1. Bivalirudin in 0.9 percent sodium chloride injection is an anticoagulant intended for patients undergoing percutaneous coronary intervention.
2. The medication "is the first and only available in a convenient frozen premixed solution," said Robert Felicelli, president of pharmaceuticals for Baxter.
3. Baxter plans to launch Bivalirudin in two different dosages in early 2018.